PF-3845 is a piperidine urea compound, which acts as a fatty acid amide hydrolase (FAAH) inhibitor degrading n-acyl ethanolamines (NAEs). Studies suggest that PF-3845 shows an anti-allodynic phenotype in rats. It is known that PF-3845 functions by irreversibly binding to Ser241 of FAAH at the catalytic sites via carbamylation. This causes an increase in arachidonoyl ethanolamide (AEA) in brain tissue and plasma in rats. PF-3845 has a Ki = 0.23 μM to the FAAH receptor. Various studies conclude that PF-3845 is an important pharmacological tool in determining the function of the endocannabinoid system.
1. Ahn, K., et al. 2009. Chem. Biol. 16: 411-420. PMID: 19389627
2. Long, J.Z., et al. 2011. J. Lipid Res. 52: 337-344. PMID: 21097653
3. Kinsey, S.G., et al. 2011. Pharmacol. Biochem. Behav. 98: 21-27. PMID: 21145341
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.